For example, the EGFR targeted therapy erlotinib in combination with a BH3 mimetic induced prolonged quiescence in preclinical models of NSCLC xenografts (198), suggesting that therapeutic approaches that achieve disease control in the long term may require combination therapies that simultaneously inhibit mitogenic and apoptotic signaling pathways. Here, EGFR is linked to non-small cell lung carcinoma.